A4M Certification Study Guide 2026 – Anti-Aging & Functional Medicine Board Exam Review

A4M CERTIFICATION STUDY GUIDE 2026 –
ANTI-AGING & FUNCTIONAL MEDICINE
BOARD EXAM REVIEW
A4M CERTIFICATION STUDY GUIDE 2026 – ANTI-AGING & FUNCTIONAL
MEDICINE BOARD EXAM REVIEW

DOCUMENT OVERVIEW:

• Comprehensive 200-question study resource designed to reinforce mastery of
anti-aging and functional medicine principles across all major certification domains;
optimized for active recall and clinical application through detailed, evidence-based
rationales.

• Study strategy: Work through questions sequentially, review rationales thoroughly
regardless of answer choice, and utilize incorrect options as learning opportunities
to deepen understanding of nuanced clinical concepts.



QUESTION 1:

Which of the following theories of aging best explains the progressive loss of
telomere length in somatic cells over time?

A) The free radical theory of aging

B) The telomere shortening theory

C) The protein misfolding theory

D) The mitochondrial dysfunction theory

E) The evolutionary antagonistic pleiotropy theory

CORRECT ANSWER: B) The telomere shortening theory

Rationale: Telomeres are repetitive DNA sequences (TTAGGG) located at
chromosome ends that shorten with each cell division due to incomplete DNA
replication (the "end-replication problem"). When telomeres reach critically short
lengths, cells enter senescence or apoptosis, contributing to aging phenotypes. This
mechanism explains cellular aging at the molecular level and correlates with
biological age markers. While other theories address different aging mechanisms,

,the telomere shortening theory specifically explains progressive loss of telomere
length. Telomerase activity, which maintains telomeres, naturally decreases in
somatic cells with age, except in stem cells and germ cells.



QUESTION 2:

A 58-year-old woman presents with night sweats, mood changes, and
irregular menstrual cycles. Which hormone assessment should be prioritized
in evaluating menopausal transition?

A) Thyroid-stimulating hormone (TSH) only

B) Serum estradiol and follicle-stimulating hormone (FSH)

C) Prolactin and adrenocorticotropic hormone (ACTH)

D) Luteinizing hormone (LH) and testosterone

E) Progesterone and cortisol ratios

CORRECT ANSWER: B) Serum estradiol and follicle-stimulating hormone
(FSH)

Rationale: During perimenopause and menopause, FSH rises significantly as
negative feedback from declining estradiol decreases, making FSH elevation a key
diagnostic marker. Serum estradiol levels become erratic during perimenopause
(fluctuating high-to-low) and progressively decline during menopause. An elevated
FSH (>30 mIU/mL) combined with low estradiol (<30 pg/mL) confirms
postmenopausal status. While TSH should be assessed to exclude thyroid
dysfunction (which mimics menopausal symptoms), it is not the priority hormone
for confirming menopausal transition. The other options do not directly assess
ovarian function decline.



QUESTION 3:

,Which bioidentical hormone formulation has the most favorable risk profile
for cardiovascular events when compared to synthetic conjugated estrogens
in hormone replacement therapy?

A) Conjugated equine estrogens (CEE)

B) Micronized 17β-estradiol

C) Medroxyprogesterone acetate (MPA)

D) Norethindrone acetate

E) Levonorgestrel

CORRECT ANSWER: B) Micronized 17β-estradiol

Rationale: Micronized 17β-estradiol is the bioidentical form of estradiol that most
closely mimics endogenous hormone structure and metabolism. Studies,
particularly the French E3N-EPIC cohort, demonstrate improved cardiovascular
outcomes with transdermal 17β-estradiol combined with micronized progesterone
compared to conjugated equine estrogens (CEE) with medroxyprogesterone
acetate (MPA) used in the WHI study. The synthetic progestins (MPA,
norethindrone, levonorgestrel) carry significantly higher thrombotic and
cardiovascular risks than micronized progesterone. Bioidentical 17β-estradiol has
less impact on coagulation factors and inflammatory markers than CEE,
contributing to improved cardiovascular safety profiles.



QUESTION 4:

A 65-year-old male with hyperlipidemia and hypertension is interested in
cardiovascular risk reduction through functional medicine optimization.
Which single marker best predicts cardiovascular event risk independent of
LDL cholesterol levels?

A) High-density lipoprotein (HDL) cholesterol

B) Apolipoprotein B (ApoB)

C) Lipoprotein(a) [Lp(a)]

, D) Triglyceride-to-HDL ratio

E) Non-HDL cholesterol

CORRECT ANSWER: C) Lipoprotein(a) [Lp(a)]

Rationale: Lipoprotein(a), a genetically determined variant of LDL, is an
independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and
thrombotic events. Elevated Lp(a) increases cardiovascular risk 2-4 fold and
remains predictive even with optimal LDL cholesterol levels. Unlike modifiable lipid
parameters, Lp(a) is largely genetically determined (>80%), making it valuable for
identifying high-risk individuals who may require more aggressive preventive
strategies. The other options reflect risk factors but are not independent predictors
to the same degree as Lp(a), and are more modifiable through lifestyle and
pharmacological intervention.



QUESTION 5:

Which dietary pattern demonstrates the most robust evidence for reducing
cardiovascular mortality and reversing atherosclerotic plaques in functional
medicine practice?

A) Low-carbohydrate ketogenic diet

B) Plant-based Mediterranean diet with emphasis on whole grains and olive oil

C) High-protein paleo diet

D) Low-fat vegan diet

E) Intermittent fasting protocol

CORRECT ANSWER: B) Plant-based Mediterranean diet with emphasis on
whole grains and olive oil

Rationale: The Mediterranean diet, particularly with added emphasis on plant-
based components, demonstrates the strongest evidence for cardiovascular
protection and atherosclerotic plaque reversal. The PREDIMED trial showed
significant reductions in cardiovascular events with Mediterranean diet